About Us
Company Overview
BriSTAR Immunotech is a clinical-stage cell therapy company dedicated to the development and commercialization of innovative engineered T cell immunotherapy products for autoimmune diseases, hematological malignancies and solid tumors. The company has obtained 2 China IND clinical approvals and 1 FDA orphan drug designation; it has filed nearly 100 invention patents globally and been granted more than 10 Chinese invention patents and PCT patents. We will continue to accelerate clinical translation and industrialization to drive the upgrading of cellular therapy.
Founded in 2018 by Dr. Lin Xin, a world-leading molecular immunologist from Tsinghua University, he is a distinguished expert in T-cell signaling with outstanding academic achievements. As a tenured professor at Tsinghua University and Lead Scientist at Changping National Laboratory(CPNL), he has received top international awards, authored over 120 high-impact papers, and held senior leadership roles at MD Anderson Cancer Center.